Conferences
SUO 2023: Primary Chemoablation for Recurrent Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer: The ENVISION Trial
November 30, 2023
SUO 2023: The Role of Biomarkers for UTUC Risk Stratification
November 30, 2023
SUO 2023: UTUC: Chemoablation and Renal Preservation is the Future
November 30, 2023
SUO 2023: Advances in Radiotherapy for Penile Cancer
November 30, 2023
SUO 2023: Robotic Inguinal Lymph Node Dissection
November 30, 2023
SUO 2023: Updates from the InPACT Trial
November 30, 2023
SUO 2023: Bladder Cancer Debate for MIBC: Trimodality Therapy/Radiotherapy after Complete Clinical Response
November 30, 2023
SUO 2023: Bladder Cancer Debate for MIBC: Neoadjuvant Chemotherapy Followed by Surveillance if Complete Clinical Response
November 30, 2023
SUO 2023: Bladder Cancer Debate for MIBC: Radical Cystectomy SHOULD be Performed after Achieving cT0 after Neoadjuvant Chemotherapy
November 29, 2023
SUO 2023: PSMA Radioligands: Current and Future
November 29, 2023
New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
November 29, 2023